Molecular Medicine Unit, St. James's
University Hospital, University of Leeds, Leeds LS9 7TF, United
Kingdom,1 and Institut für
Klinische und Molekulare Virologie der
Friedrich-Alexander-Universität Erlangen-Nürnberg,
D-91054 Erlangen, Germany2
Herpesviruses occur in two distinct forms of infection, lytic
replication and latent persistence. In this study, we investigated the
molecular mechanisms that govern the latent-lytic switch in the
prototype gamma-2 herpesvirus, herpesvirus saimiri (HVS). We utilized a
persistently HVS-infected A549 cell line, in which HVS DNA is stably
maintained as nonintegrated circular episomes, to assess the role of
the open reading frame 50 (ORF 50) (Rta) proteins in the latent-lytic
switch. Northern blot analysis and virus recovery assays determined
that the ORF 50a gene product, when expressed under the control of a
constitutively active promoter, was sufficient to reactivate the entire
lytic replication cycle, producing infectious virus particles.
Furthermore, although the ORF 50 proteins of HVS strains A11 and C488
are structurally divergent, they were both capable of inducing the
lytic replication cycle in this model of HVS latency.
 |
TEXT |
Herpesviruses are characterized by
two distinct forms of infection, lytic replication and latent
persistence. An important aspect of herpesvirus biology, which is still
relatively poorly understood, is the switch from latency to the lytic
replication cycle. Among gammaherpesviruses, the molecular mechanisms
that govern the latent-lytic switch have been most widely studied in B
cells latently infected with Epstein-Barr virus (EBV). EBV encodes two
immediate-early (IE) proteins that regulate initiation of the
lytic replication cycle, namely, Zta (also termed BZLF1, Zebra, and Z)
and Rta (also termed BRLF1 and R) (reviewed in reference 16). Expression of Zta, in transient transfection
experiments, is sufficient to reactivate lytic gene expression from
latently EBV-infected cells (3, 6, 27, 29), and
consequently Zta has been implicated as the molecular switch for
reactivation. However, recent analyses have demonstrated that transient
expression of Rta, although not always sufficient to disrupt latency,
activates lytic gene expression in certain cell lines latently infected with EBV (25, 26, 37). Furthermore, expression of the
Kaposi's sarcoma-associated herpesvirus (KSHV) and murine
gammaherpesvirus 68 (MHV-68) open reading frame 50 (ORF 50)
(Rta) homologues has been shown to disrupt the latent state and induce
the lytic replication cycle in B cell lines latently infected with KSHV
(5, 20, 28) and MHV-68 (35), respectively.
Herpesvirus saimiri (HVS), the prototype gamma-2 herpesvirus,
establishes an asymptomatic infection in its natural host, the squirrel
monkey (Saimiri sciureus), but causes fatal T-cell lymphomas and lymphoproliferative diseases in other species of New World primates
(1, 4). Little is known regarding the molecular mechanisms
that govern the HVS latent-lytic switch, which is due partly to the
lack of a suitable tissue culture model of HVS latency. Although
growth-transformed human T cells harbor the viral genome of HVS strain
C488 (a subgroup C strain) as nonintegrating episomes in high
copy number without production of virus particles (2, 15),
chemical inducing agents are unable to reactivate the lytic replication
cycle (17). Furthermore, the small detectable amounts of
ORF 50 transcripts in stimulated HVS-transformed human T cells are not
sufficient to induce virus replication (17, 30). Other cell types, such as various kidney cell lines, are relatively permissive for HVS. We recently reported the development of a system in
which the genome of HVS strain A11 (a subgroup A strain) is stably
maintained as nonintegrated circular episomes in the human lung
carcinoma cell line A549 (12). Northern blot analysis has
shown that a set of genes encoding ORFs 71 to 73 are strongly expressed
in this persistently infected cell line, in contrast to transformed
human T cells. Moreover, the full lytic replication cycle, producing
infectious virions, can be reactivated in A549 cells by chemical
inducing agents including tetradecanoyl phorbol acetate (TPA) and
n-butyrate (12). Therefore, we believe this model provides a useful system for further study of the molecular mechanisms of the latent-lytic switch in HVS and gamma-2 herpesviruses in general.
Gene expression during the HVS lytic replication cycle is controlled by
the products of the two major transcriptional regulatory genes encoded
by ORFs 50 and 57; no homologue of the Z protein has as yet been
identified (1, 24, 32-34). We have shown previously that
the ORF 50 gene encodes two products which activate delayed-early (DE)
transcription directly following interactions with promoters containing
a specific ORF 50 recognition sequence (24, 31, 32).
Furthermore, ORF 50 contains a well conserved carboxy-terminal activation domain required for ORF 50 transactivation and for interaction with the general cellular transcription factor TATA-binding protein (TBP) (11). Surprisingly, we have observed
considerable sequence divergence between the ORF 50 genes of HVS
strains A11 and C488, which may lead to altered transactivation
properties (30).
In this study, we utilized the persistently HVS-infected cell line A549
to investigate the role of the HVS ORF 50 proteins in the latent-lytic
switch. Transient transfection assays were performed with a range of
ORF 50 expression constructs. Northern blot analysis and virus recovery
assays determined that the spliced ORF 50a gene product, when expressed
under the control of a constitutively active promoter, was sufficient
to reactivate the entire HVS lytic replication cycle. Furthermore,
although the HVS A and C strain ORF 50 proteins are structurally
divergent, they are both capable of inducing the lytic replication
cycle in this model of HVS latency.
HVS ORF 50 (Rta) protein reactivates late viral gene expression in
the persistently HVS-infected cell line A549.
To determine whether
the HVS ORF 50a or 50b protein can induce late viral gene expression in
the persistently HVS-infected cell line A549, reactivation studies and
Northern blot analysis were performed. HVS-infected A549 cells remained
uninduced, were incubated in the presence of either 3 mM
n-butyrate (Sigma, Dorset, United Kingdom) or 20 ng
of TPA (Sigma) per ml, or were transfected with 2 µg of either
pORF50aA (a plasmid expressing the strain A11 ORF 50a coding region
under the control of its own promoter [32]),
pHincIIA (a plasmid expressing the strain A11 ORF 50b coding
region under the control of its own promoter [32]), or pCMV50aA or pCMV50bA (which are under the control of the
cytomegalovirus [CMV] IE enhancer-promoter [Fig.
1a]). All transfections were performed using 2 µg of the appropriate DNA in conjunction with the
Lipofectamine transfection reagent (Life Technologies), as directed by
the manufacturer. Transfection efficiency was normalized by using a
control plasmid, pCMV
(Clontech), expressing
-galactosidase. In
order to generate pCMV50aA and pCMV50bA, the coding regions of strain
A11 ORF 50a and ORF 50b were PCR amplified from pORF50aA with the
following sets of forward and reverse primers: 50aF (5' AAA CTG CAG GCA
ACA ACA ATG ACA CAC AAG), 50bF (5' AAA CTG CAG TAT ATC ATG CAG CGC CTT
GTA), and 50R (5' AAA CTG CAG CCT TCA TCA TCT ACA TCA GTG). These
oligonucleotides contain PstI restriction sites for
convenient cloning of these products into the eukaryotic expression vector pcDNA3.1 to derive pCMV50aA and pCMV50bA.
The integrity of all constructs was confirmed by DNA sequencing. After 30 h, total RNA was isolated and reverse transcription
(RT)-PCR and Northern blot analysis were performed. RT-PCR was utilized to confirm the expression of the ORF 50 gene products.
First-strand cDNA was reverse-transcribed using Superscript II
reverse transcriptase (Life Technologies) and an oligo(dT)
primer; cDNA was then amplified by PCR using the ORF 50 gene-specific
primers 50bF and 50R. The results demonstrated that ORF 50a or 50b gene
products were expressed in all transfection experiments (data not
shown). In order to determine whether the HVS ORF 50 (Rta) proteins can
induce late viral gene expression in the persistently HVS-infected A549
cell line, RNA was separated by electrophoresis on a 1% denaturing formaldehyde agarose gel, transferred to Hybond-N membranes, and hybridized with a 32P-radiolabeled probe specific
for the HVS late major capsid protein (MCP) (ORF 25) or gB (ORF 8)
coding sequences (Fig. 1b). The results of Northern blot analysis
suggest that, in contrast with the smaller, unspliced ORF 50b
construct, expression of the larger, spliced ORF 50a gene product,
under the control of the constitutively active CMV IE
enhancer-promoter, is sufficient to reactivate late gene expression in
the HVS-infected A549 cell line. Interestingly, no reactivation was
observed when ORF 50a was expressed from its cognate promoter elements.
This suggests that regulation of the ORF 50a promoter itself may be a
factor governing reactivation of the HVS lytic cycle.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 1.
ORF 50 induces late gene expression from the
persistently HVS-infected cell line A549. (a) Schematic representation
of the intron-exon structure of the HVS strain A11 ORF 50 gene
products. (b) HVS-infected A549 cells incubated in control medium were
uninduced (mock) or incubated in the presence of 3 mM
n-butyrate or 20 ng of TPA/ml or were transfected with 2 µg of pORF50aA, pHincIIA, pCMV50aA, or
pCMV50bA. After 30 h, total RNA was isolated and separated
by electrophoresis on a 1% denaturing formaldehyde agarose gel. RNA
was transferred to Hybond-N membranes and hybridized with
32P-radiolabeled probes specific for the HVS MCP (ORF 25)
(i) and gB (ORF 8) (ii) coding regions. Hybridization loading controls
are shown with a glyceraldehyde-3-phosphate dehydrogenase probe
(iii).
|
|
HVS ORF 50 (Rta) reactivation is dependent on viral DNA
synthesis.
To elucidate the kinetics of lytic gene expression
activated by ORF 50, RNA was harvested at various times postinduction
and Northern blot analysis was performed using probes specific for DE
and late genes. HVS-infected A549 cells remained uninduced, were
incubated in the presence of either n-butyrate or TPA, or were transfected with pCMV50aA, as previously described. Total RNA was harvested at 12 and 30 h postinduction, and Northern blot analysis was performed using 32P-radiolabeled
probes specific for the DE major DNA-binding protein (mDBP) (ORF 6) and
the late MCP (ORF 25). At 12 h postinduction, the DE mDBP gene was
stimulated approximately fourfold; however, the late MCP transcript was
absent. In contrast, at 30 h a marked induction of late gene
expression was clearly evident (Fig. 2). This suggested that reactivation by ORF 50a leads to the appropriate temporal regulation of lytic virus gene expression.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
ORF 50 reactivation is dependent on viral DNA synthesis.
HVS-infected A549 cells incubated in control medium were uninduced
(mock) or incubated in the presence of 3 mM n-butyrate
or 20 ng of TPA/ml or were transfected with 2 µg of pCMV50aA. The
leftmost four lanes in each panel remained untreated, whereas the
rightmost four lanes were incubated in the presence of PAA (200 µg/ml). Total RNA was harvested at 12 h (a) and 30 h (b)
postinduction and separated by electrophoresis on a 1% denaturing
formaldehyde agarose gel. RNA was transferred to Hybond-N membranes and
hybridized with 32P-radiolabeled probes specific for the
HVS mDBP (ORF 6) (i) and MCP (ORF 25) (ii) coding regions.
Hybridization loading controls are shown with a
glyceraldehyde-3-phosphate dehydrogenase probe (iii).
|
|
Furthermore, to confirm the kinetics of late gene expression upon ORF
50 reactivation, phosphonoacetic acid (PAA), an inhibitor of viral DNA
synthesis, was utilized. The above experiment was repeated in the
presence of PAA. Results showed that expression of DE ORF 6 gene
expression was unaffected by the presence of PAA. However, PAA
inhibited late capsid gene expression in both induced and ORF
50-transfected cells (Fig. 2). This indicates that viral DNA synthesis
is required for ORF 50-induced late gene expression.
HVS ORF 50 (Rta) induces infectious virus particle production from
persistently HVS-infected A549 cells.
As demonstrated above,
expression of ORF 50 reactivates viral lytic gene expression. To
determine whether expression of ORF 50 is sufficient to induce the
entire lytic replication cycle, leading to production of infectious
virus particles in the persistently HVS-infected A549 cell line, virus
recovery assays were performed. HVS-infected A549 cells remained
uninduced, were incubated in the presence of either
n-butyrate or TPA, or were transfected with 2 µg of
pCMV50aA or pCMV50bA, as previously described. After 96 h,
serial dilutions of the harvested supernatants were used to infect
permissive OMK cells. After 1 h at 37°C, the supernatants were
removed and replaced with medium supplemented with 2% fetal calf serum
and 0.45% (wt/vol) high-viscosity carboxymethyl cellulose (Sigma). The
mixtures were transferred to dishes and incubated at 37°C for 5 to 7 days postinfection. The infected cells were subsequently fixed in
formol-saline solution (0.85% [wt/vol] NaCl and 10% [vol/vol]
formaldehyde) and stained with 0.1% (wt/vol) Gentian violet, and
plaques were counted (Fig. 3). The
results demonstrate that a significant increase in PFU was observed
from supernatants taken from the chemically induced and
pCMV50aA-transfected cell lines. A very low level of virus
production was observed in the uninduced cell line, suggesting that
weak spontaneous replication occurs in the persistently infected A549
cell line, as previously reported (12). However, the
induction experiment clearly suggested that in HVS-infected A549 cells,
ORF 50a expression can induce reactivation, leading to infectious virus
production.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 3.
ORF 50 reactivates infectious virus production from the
persistently HVS-infected cell line A549. HVS-infected A549 cells
incubated in control medium were uninduced (mock) or incubated in the
presence of 3 mM n-butyrate or 20 ng of TPA/ml or were
transfected with 2 µg of pCMV50aA or pCMV50bA. After 96 h of
induction, virus recovery assays were performed. Numbers of plaques
formed are shown graphically, and the variations between three
replicated assays are indicated.
|
|
The divergent C strain ORF 50 (Rta) protein reactivates the
complete lytic replication cycle from persistently HVS-infected A549
cells.
We previously demonstrated a pronounced structural
divergence between the ORF 50 genes of HVS strains A11 and C488 (Fig.
4a) (30). To assess whether
expression of the divergent C488 ORF 50 could also induce reactivation
from the persistently infected A549 cell line, virus recovery assays
were performed as described above. The ORF 50a and ORF 50b genes of
strain C488 were inserted into a eukaryotic expression vector under the
control of the CMV IE promoter. The coding region of the spliced ORF50a
cDNA from C488 was amplified by RT-PCR using the oligonucleotide
primers HF317 (5' ATG ACA CAC AAG CCT G [forward]) and
HF377 (5' GCT TTA TTC ATC AGT TAC TAA ATC [reverse]) and
Pwo polymerase (Roche Diagnostics, Mannheim,
Germany). The ORF 50a cDNA fragment was first cloned into the
pCR-Blunt vector (Invitrogen, Groningen, The Netherlands) and, after
sequence confirmation, was subcloned into the expression vector
pcDNA3.0 (Invitrogen). The unspliced ORF50b fragment was amplified
using the primers HF458 (5' GGT ACC GCC ACC ATG GGA CTA GGA AAA GAA ATA
AC [incorporating a KpnI cleavage site]) and HF436 (5' GCG
GCC GCT TAT TCA TCA GTT ACT AAA TC [including a NotI
cleavage site]) and sequenced after being cloned into the pSTBlue-1
AccepTor vector (Novagen, Madison, Wis.). The
KpnI-NotI fragment was subcloned into pcDNA3.0,
yielding the expression plasmid pCMV50bC. HVS-infected A549 cells were
transfected with 2 µg of either pCMV50aC or pCMV50bC, as previously
described. RT-PCR was utilized to confirm the expression of the ORF 50 A and C strain gene products with ORF 50 A and C strain-specific primers, as previously described. The supernatants were then
harvested at 96 h posttransfection and used in virus recovery
assays. Chemically induced pCMV50aA- and pCMV50bA (A
strain)-transfected cells were also used as suitable controls and, as
expected, resulted in a significant increase in infectious virus
production in all cases except with pCMV50b. Furthermore, transfection
with pCMV50aC resulted in reactivation and infectious virus production
from the persistently HVS-infected A549 cells (Fig. 4b). This suggests
that, although divergent, the ORF 50a genes between HVS A and C strains
are functionally homologous and are sufficient for reactivation of the
entire lytic replication cycle.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
The divergent ORF 50 of subgroup C strains can induce
infectious virus production in the persistently HVS-infected cell line
A549. (a) Sequence divergence between ORF 50 genomic regions of HVS
strains A11 and C488. (b) HVS-infected A549 cells incubated in control
medium were uninduced (mock) or incubated in the presence of 3 mM
n-butyrate (lane 2) or 20 ng of TPA/ml or were
transfected with 2 µg of pCMV50aA, pCMV50bA, pCMV50aC, or pCMV50bC.
After 96 h of induction, virus recovery assays were performed.
Numbers of plaques formed are shown graphically, and the variations
between three replicated assays are indicated.
|
|
In this study, we have demonstrated that the HVS ORF 50a (Rta) protein
is sufficient for the disruption of latency in a persistently HVS-infected A549 cell line in which the viral genome remains as a
circular nonintegrated episome. Interestingly, only the larger, spliced
transcript of HVS ORF 50 is sufficient to initiate late gene expression
and virus production. Similar observations with other
gammaherpesviruses, including KSHV and MHV-68 (5, 20, 28,
35), have been made. In all cases, ORF 50 is encoded by a
spliced transcript containing the first exon in or upstream of ORF 49 (5, 19, 20, 35). This is in contrast to the EBV Rta gene
product, which is encoded by an unspliced transcript. Moreover, the EBV
and KSHV ORF 50 transcripts are bicistronic and polycistronic,
respectively, both encoding the Zta gene product (10, 18, 23,
39). At present, no Zta homologue in HVS has been identified
(1). Thus, the results herein suggest that the role of the
ORF 50 gene product is conserved in gammaherpesviruses.
We have previously shown that HVS ORF 50 encodes a sequence-specific
transcriptional activator (31, 32). Intriguingly, the
gammaherpesvirus ORF 50 proteins all appear to be distinct activators
containing limited, if any, homology to known cellular transcriptional
activators. Both HVS and EBV ORF 50 proteins have been shown to
directly interact with DNA, recognizing distinct response elements
(7-9, 31). However, no obvious DNA-binding motif has yet
been identified. Sequence analysis demonstrates that the amino termini
of the ORF 50 proteins have more-pronounced similarity, and with
respect to EBV, this region is required for dimerization and DNA
binding (21). Moreover, the extreme carboxy terminus
contains a positionally conserved activation domain, which is required
for interaction of the HVS and EBV ORF 50 proteins with the general
transcription factor TBP (11, 13, 14, 22). In addition, it
is interesting to note that although there is considerable interstrain
sequence divergence between the HVS ORF 50 proteins, their amino- and
carboxy-terminal domains are conserved, allowing these proteins to be
functionally homologous (30). The conserved function of
the divergent ORF 50 alleles in the reactivation of lytic virus
replication suggests that the structural and functional variations of
this gene in subgroup C HVS strains (30) might rather be
related to the transformation of T lymphocytes, supplementing the viral
genes STP-C and Tip, which are necessary for transformation.
The results herein also highlight the regulation of ORF 50 expression
as a major factor of the molecular mechanism governing the
latent-lytic switch. We have shown that expression of the ORF 50 protein under the control of its cognate promoter is insufficient to
disrupt latency in the persistently HVS-infected cell line A549.
However, when expressed under the control of the constitutively active
CMV IE promoter, lytic gene expression and virus production are
activated. Therefore, regulation of the ORF 50 promoter by cellular
factors is central in maintenance of the latent state or viral
reactivation. A similar hypothesis has been proposed for EBV
(26). During latency, both the Zta and Rta promoters are
repressed by cellular factors, chromatin structure, and/or the lack of
specific cellular activators. Upon induction, these cellular factors
are displaced and the chromatin structure is modified by activating
cellular factors, in addition to autostimulatory effects. For example,
the Zif268 and Sp1 factors have been implicated in activation of the
Rta promoter, leading to the induction of lytic gene expression
(36, 38). At present, identification of cellular factors
that regulate the HVS ORF 50 promoter is being undertaken to determine
their precise role in the onset of viral pathogenesis.
This work was supported in part by grants to A.W. from the Medical
Research Council and Yorkshire Cancer Research and by grants to H.F.
from Deutsche Forschungsgemeinschaft and Bayerische Forschungsstiftung.
| 1.
|
Albrecht, J. C.,
J. Nicholas,
D. Biller,
K. R. Cameron,
B. Biesinger,
C. Newman,
S. Wittman,
M. A. Craxton,
H. Coleman,
B. Fleckenstein, and R. W. Honess.
1992.
Primary structure of the herpesvirus saimiri genome.
J. Virol.
66:5047-5058[Abstract/Free Full Text].
|
| 2.
|
Biesinger, B.,
I. Müller-Fleckenstein,
B. Simmer,
G. Lang,
S. Wittmann,
E. Platzer,
R. C. Desrosiers, and B. Fleckenstein.
1992.
Stable growth transformation of human T lymphocytes by herpesvirus saimiri.
Proc. Natl. Acad. Sci. USA
89:3116-3119[Abstract/Free Full Text].
|
| 3.
|
Countryman, J., and G. Miller.
1985.
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterologous DNA.
Proc. Natl. Acad. Sci. USA
82:4085-4089[Abstract/Free Full Text].
|
| 4.
|
Fleckenstein, B., and R. C. Desrosiers.
1982.
Herpesvirus saimiri and herpesvirus ateles, p. 253-332.
In
B. Roizman (ed.), The herpesviruses, vol. 1. Plenum Press, New York, N.Y.
|
| 5.
|
Gradoville, L.,
J. Gerlach,
E. Grogan,
D. Shedd,
S. Nikiforow,
C. Metroka, and G. Miller.
2000.
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic replication cycle in the HH-B2 primary effusion lymphoma cell line.
J. Virol.
74:6207-6212[Abstract/Free Full Text].
|
| 6.
|
Grogan, E. J.,
J. Jenson,
J. Countryman,
L. Heston,
L. Gradoville, and G. Miller.
1987.
Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr virus infection to productive infection in lymphoid cells.
Proc. Natl. Acad. Sci. USA
84:1332-1336[Abstract/Free Full Text].
|
| 7.
|
Gruffat, H., and A. Sergeant.
1994.
Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R.
Nucleic Acids Res.
22:1172-1178[Abstract/Free Full Text].
|
| 8.
|
Gruffat, H.,
E. Manet,
A. Rigolet, and A. Sergeant.
1990.
The enhancer factor R of Epstein-Barr virus (EBV) is a sequence specific DNA binding protein.
Nucleic Acids Res.
18:6835-6843[Abstract/Free Full Text].
|
| 9.
|
Gruffat, H.,
N. Duran,
M. Buisson,
F. Wild,
R. Buckland, and A. Sergeant.
1992.
Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter.
J. Virol.
66:46-52[Abstract/Free Full Text].
|
| 10.
|
Gruffat, H.,
S. Portes-Sentis,
A. Sergeant, and E. Manet.
1999.
Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) encodes a homologue of the Epstein-Barr virus bZip protein EB1.
J. Gen. Virol.
80:557-561[Abstract].
|
| 11.
|
Hall, K. T.,
A. J. Stevenson,
D. J. Goodwin,
P. C. Gibson,
A. F. Markham, and A. Whitehouse.
1999.
The activation domain of the herpesvirus saimiri R protein interacts with the TATA-binding protein.
J. Virol.
73:9756-9763[Abstract/Free Full Text].
|
| 12.
|
Hall, K. T.,
M. S. Giles,
D. J. Goodwin,
M. A. Calderwood,
I. M. Carr,
A. J. Stevenson,
A. F. Markham, and A. Whitehouse.
2000.
Analysis of gene expression in a human cell line stably transduced with herpesvirus saimiri.
J. Virol.
74:7331-7337[Abstract/Free Full Text].
|
| 13.
|
Hardwicke, J. M.,
L. Tse,
N. Applegren,
J. Nicholas, and M. A. Veliuona.
1992.
The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activator domain with properties different from those of VP16.
J. Virol.
66:5500-5508[Abstract/Free Full Text].
|
| 14.
|
Hardwicke, J. M.,
P. M. Liberman, and S. D. Hayward.
1988.
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen.
J. Virol.
62:2274-2284[Abstract/Free Full Text].
|
| 15.
|
Kaschka-Dierich, C.,
F. J. Werner,
I. Bauer, and B. Fleckenstein.
1982.
Structure of nonintegrated, circular Herpesvirus saimiri and Herpesvirus ateles genomes in tumor cell lines and in vitro-transformed cells.
J. Virol.
44:295-310[Abstract/Free Full Text].
|
| 16.
|
Kieff, E.
1996.
Epstein-Barr virus and its replication, p. 2343-2396.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 17.
|
Knappe, A.,
C. Hiller,
M. Thurau,
S. Wittman,
H. Hofmann,
B. Fleckenstein, and H. Fickenscher.
1997.
The superantigen-homologous viral immediate-early gene ie14/vsag in herpesvirus saimiri-transformed human T cells.
J. Virol.
71:9124-9133[Abstract].
|
| 18.
|
Lin, S.-F.,
D. R. Robinson,
G. Miller, and H.-J. Kung.
1999.
Kaposi's sarcoma-associated herpesvirus encodes a bZip protein with homology to BZLF1 of Epstein-Barr virus.
J. Virol.
73:1909-1917[Abstract/Free Full Text].
|
| 19.
|
Liu, S.,
I. V. Pavlova,
H. W. Virgin, IV, and S. H. Speck.
2000.
Characterization of gammaherpesvirus 68 gene 50 transcription.
J. Virol.
74:2029-2037[Abstract/Free Full Text].
|
| 20.
|
Lukac, D. M.,
R. Renne,
J. R. Kirshner, and D. Ganem.
1998.
Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein.
Virology
252:304-312[CrossRef][Medline].
|
| 21.
|
Manet, E.,
A. Rigolet,
H. Gruffat,
J. F. Giot, and A. Sergeant.
1991.
Domains of the Epstein-Barr virus transcription factor R required for dimerisation, DNA binding and activation.
Nucleic Acids Res.
19:2661-2667[Abstract/Free Full Text].
|
| 22.
|
Manet, E.,
C. Allera,
H. Gruffat,
I. Mikaelian,
A. Rigolet, and A. Sergeant.
1993.
The acidic activation domain of the EBV transcription factor interacts in vitro with both TBP and TFIIB and is cell-specifically potentiated by a proline-rich region.
Gene Expr.
3:49-59[Medline].
|
| 23.
|
Manet, E.,
H. Gruffat,
M. C. Trescol-Biemont,
I. Moreno,
P. Chambard,
J. F. Giot, and A. Sergeant.
1989.
Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators.
EMBO J.
8:1819-1826[Medline].
|
| 24.
|
Nicholas, J.,
L. S. Coles,
C. Newman, and R. W. Honess.
1991.
Regulation of the herpesvirus saimiri (HVS) delayed-early 110-kilodalton promoter by HVS immediate-early gene products and a homolog of the Epstein-Barr virus R trans activator.
J. Virol.
65:2457-2466[Abstract/Free Full Text].
|
| 25.
|
Ragoczy, T., and G. Miller.
1999.
Role of the Epstein-Barr virus Rta protein in activation of distinct classes of viral lytic cycle genes.
J. Virol.
73:9858-9866[Abstract/Free Full Text].
|
| 26.
|
Ragoczy, T.,
L. Heston, and G. Miller.
1998.
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.
J. Virol.
72:7978-7984[Abstract/Free Full Text].
|
| 27.
|
Rooney, C. M.,
D. T. Rowe,
T. Ragot, and P. J. Farrell.
1989.
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle.
J. Virol.
64:5295-5300.
|
| 28.
|
Sun, R.,
S. F. Lin,
L. Gradoville,
Y. Yuan,
F. Zhu, and G. Miller.
1998.
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.
Proc. Natl. Acad. Sci. USA
95:10866-10871[Abstract/Free Full Text].
|
| 29.
|
Takada, K.,
N. Shimuzu,
S. Sakuma, and A. Keating.
1986.
Transactivation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV BamHI Z DNA fragment.
J. Virol.
57:1016-1022[Abstract/Free Full Text].
|
| 30.
|
Thurau, M.,
A. Whitehouse,
S. Wittmann,
D. M. Meredith, and H. Fickenscher.
2000.
Distinct transcriptional and functional properties of the R transactivator gene ORF 50 of the transforming herpesvirus saimiri strain C488.
Virology
268:167-177[CrossRef][Medline].
|
| 31.
|
Whitehouse, A.,
A. J. Stevenson,
M. Cooper, and D. M. Meredith.
1997.
Identification of a cis-acting element within the herpesvirus saimiri ORF6 promoter that is responsive to the HVS.R transactivator.
J. Gen. Virol.
78:1411-1415[Abstract].
|
| 32.
|
Whitehouse, A.,
I. M. Carr,
J. C. Griffiths, and D. M. Meredith.
1997.
The herpesvirus saimiri ORF50 gene, encoding a major transcriptional activator homologous to the Epstein-Barr virus R protein, is transcribed from two distinct promoters of different temporal phases.
J. Virol.
71:2550-2554[Abstract].
|
| 33.
|
Whitehouse, A.,
M. Cooper, and D. M. Meredith.
1998.
The immediate-early gene product encoded by open reading frame 57 of herpesvirus saimiri modulates gene expression at a posttranscriptional level.
J. Virol.
72:857-861[Abstract/Free Full Text].
|
| 34.
|
Whitehouse, A.,
M. Cooper,
K. T. Hall, and D. M. Meredith.
1998.
The open reading frame (ORF) 50a gene product regulates ORF 57 gene expression in herpesvirus saimiri.
J. Virol.
72:1967-1973[Abstract/Free Full Text].
|
| 35.
|
Wu, T.-T.,
E. J. Usherwood,
J. P. Stewart,
A. A. Nash, and R. Sun.
2000.
Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency.
J. Virol.
74:3659-3667[Abstract/Free Full Text].
|
| 36.
|
Zalani, S.,
E. Holley-Guthrie, and S. Kenney.
1995.
The Zif628 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter.
J. Virol.
69:3816-3823[Abstract].
|
| 37.
|
Zalani, S.,
E. Holley-Guthrie, and S. Kenney.
1996.
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.
Proc. Natl. Acad. Sci. USA
93:9194-9199[Abstract/Free Full Text].
|
| 38.
|
Zalani, S.,
E. Holley-Guthrie,
D. E. Gutsch, and S. Kenney.
1992.
The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor.
J. Virol.
66:7282-7292[Abstract/Free Full Text].
|
| 39.
|
Zhu, F. X.,
T. Cusano, and Y. Yuan.
1999.
Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus.
J. Virol.
73:5556-5567[Abstract/Free Full Text].
|